Evidence map›Paper›PMID 27538371›Full record

ArticleExperimental & molecular medicine2016

Sarcoplasmic reticulum Ca(2+) ATPase 2 (SERCA2) reduces the migratory capacity of CCL21-treated monocyte-derived dendritic cells.

Cheol Yi Hong, Hyun-Ju Lee, Nu-Ri Choi, Sung-Hoon Jung, Manh-Cuong Vo, My Dung Hoang, Hyeoung-Joon Kim, Je-Jung Lee

Open access · goldAbstract read
In one paragraph

Article in Experimental & molecular medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. DDX54 downregulation enhances anti-PD1 therapy in immune-desert lung tumors with high tumor mutational burden.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  2. Dendritic Cell-Hitchhiking In Vivo for Vaccine Delivery to Lymph Nodes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  3. Article
  4. Article
  5. Cellular immunotherapy in multiple myeloma.The Korean journal of internal medicine · 2019
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Cheol Yi HongResearch Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Hwasun-gun, Jellanam-do, Republic of Korea.
Hyun-Ju LeeResearch Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Hwasun-gun, Jellanam-do, Republic of Korea.
Nu-Ri ChoiResearch Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Hwasun-gun, Jellanam-do, Republic of Korea.
Sung-Hoon JungResearch Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Hwasun-gun, Jellanam-do, Republic of Korea.
Manh-Cuong VoResearch Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Hwasun-gun, Jellanam-do, Republic of Korea.
My Dung HoangResearch Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Hwasun-gun, Jellanam-do, Republic of Korea.
Hyeoung-Joon KimDepartment of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun-gun, Jellanam-do, Republic of Korea.
Je-Jung LeeResearch Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Hwasun-gun, Jellanam-do, Republic of Korea.
Chonnam National University Hwasun Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The migration of dendritic cells (DCs) to secondary lymphoid organs depends on chemoattraction through the interaction of the chemokine receptors with chemokines. However, the mechanism of how lymphoid chemokines attract DCs to lymphoid organs remains unclear. Here, we demonstrate the mechanism of DC migration in response to the lymphoid chemokine CCL21. CCL21-mediated DC migration is controlled by the regulation of sarcoplasmic reticulum Ca(2+) ATPase 2 (SERCA2) expression rather than through the activation of mitogen-activated protein kinases CCL21-exposed mature DCs (mDCs) exhibited decreased SERCA2 expression but not decreased phospholamban (PLB) or Hax-1 expression, which are known to be SERCA2-interacting proteins. In addition, CCL21 did not affect the mRNA levels of SERCA2 or its interacting protein Hax-1. Interestingly, SERCA2 expression was inversely related to DC migration in response to chemokine stimulation. The migratory capacity of CCL21-treated mDCs was decreased by the phospholipase C inhibitor U73122 and by the protein kinase C inhibitor BAPTA-AM. The migratory capacities of mDCs were increased in response to SERCA2 siRNA expression but were decreased by SERCA2 overexpression. In addition, DCs treated with a SERCA2-specific inhibitor (cyclopiazonic acid) had significantly increased migratory capacities as mDCs regardless of SERCA2 expression. Moreover, SERCA2 expression was dependent on DC maturation induced by cytokines or Toll-like receptor agonists. Therefore, the migratory capacities differed in differentially matured DCs. Taken together, these results suggest that SERCA2 contributes to the migration of CCL21-activated DCs as an important feature of the adaptive immune response and provide novel insights regarding the role of SERCA2 in DC functions.

Indexed as

ChemotaxisAdaptive ImmunityCells, CulturedChemokine CCL21Dendritic CellsHumansMonocytesSarcoplasmic Reticulum Calcium-Transporting ATPasesATP2A2 protein, humanCCL21 protein, humanChemokine CCL21Sarcoplasmic Reticulum Calcium-Transporting ATPases

Identifiers

PMID27538371
PMCPMC5007641
OpenAlexW2468171606

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.